Abel Hall LLC’s Neuronetics STIM Stock Holding History

Abel Hall LLC’s Portfolio STIM Stock Details STIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,605	Closed	-$39.5K	–	961
2025 Q4	$39.5K	Buy	+28,605	New	+$59.9K	0.01%	673

Other funds holding STIM

MAM

Madryn Asset Management New York $36.9M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Abel Hall LLC's STIM Position: Q1 2026 in Review

Abel Hall LLC sold out of Neuronetics (STIM) in Q1 2026, closing a stake of 28,605 shares — an estimated $39.5K sold.

Abel Hall LLC first reported a position in STIM in Q4 2025 and held it in 1 quarter. The position peaked at $39.5K in Q4 2025. 99 funds tracked by Wall St. Rank hold STIM as of Q1 2026.

Abel Hall LLC reported no remaining Neuronetics position as of Q1 2026 after selling out during the quarter.
Abel Hall LLC sold 28,605 Neuronetics shares in Q1 2026, an estimated $39.5K.
Abel Hall LLC first reported a position in Neuronetics in Q4 2025 and held it in 1 quarter.
Abel Hall LLC's Neuronetics position peaked at $39.5K in Q4 2025.
99 funds tracked by Wall St. Rank held Neuronetics as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.